Ruisch, I. Hyun
Dietrich, Andrea
Glennon, Jeffrey C.
Buitelaar, Jan K.
Hoekstra, Pieter J.
Funding for this research was provided by:
European Community’s Seventh Framework Programme (603016)
Article History
Received: 9 July 2018
Accepted: 6 December 2018
First Online: 19 December 2018
Compliance with ethical standards
:
: I. Hyun Ruisch, Pieter J. Hoekstra, and Andrea Dietrich reported no financial interests or potential conflicts of interest. Jan K. Buitelaar was a consultant to/member of advisory board of/and/or speaker for Janssen-Cilag BV, Eli Lilly, Shire, Novartis, Roche, and Servier. Jeffrey C. Glennon has, in the past 3 years, been a consultant to Boehringer Ingelheim GmbH. Neither Jan K. Buitelaar nor Jeffrey C. Glennon is employees of any of these companies, and neither are stock shareholders of any of these companies.